1
/
of
0
CBER Director Response – Bluebird Bio Dispute (Lyfgenia, BLA #125788)
CBER Director Response – Bluebird Bio Dispute (Lyfgenia, BLA #125788)
Regular price
$89.00 USD
Regular price
Sale price
$89.00 USD
Unit price
/
per
Request Contents: CBER Director Peter Marks' response to Bluebird Bio’s formal dispute resolution request related to the denial of a rare pediatric disease priority review voucher for Lyfgenia (BLA #125788)
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details